SEATTLE, July 8, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing (NGS) to profile the adaptive immune system, is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company's expanding Executive Leadership Team. Mr. Nolan's hire, the second management hire this month, represents Adaptive's continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.
"There are very few people in the world, especially within healthcare, that have managed the scale of data that Sean has," said Chad Robins, President and Chief Executive Officer at Adaptive Biotechnologies. "Immunosequencing, or the sequencing of a patient's immune system, will provide opportunities within research and clinical settings to leverage, aggregate, and mine data across therapeutic areas to materially impact treatment decisions. Hiring Sean as part of Adaptive's management team stresses the importance we are putting on data as a key driver to the success of our business."
Mr. Nolan's 13-year career at Microsoft spans leadership positions in healthcare software architecture, most recently as General Manager and Distinguished Engineer for HealthVault and the Health Solutions Group. Millions of families worldwide use HealthVault with mobile devices and wearable sensors to manage their health and collaborate with healthcare providers. Prior to his most recent position at Microsoft, Mr. Nolan was Chief Technology Officer of Drugstore.com and President of Software Poetry, a consulting firm where he advised venture capital firms on portfolio investments and acted as "virtual CTO" to large-scale internet services companies. Sean has a leadership voice in healthcare online as "Family Health Guy" and regularly speaks internationally on healthcare issues. Mr. Nolan was part of the founding teams that created key advances in healthcare innovation technology, including Blue Button and the Direct messaging protocol, both now part of federal standards and regulation. Sean holds a Bachelor of Arts degree in Cognitive Science from Dartmouth College.
"My career has been all about using computation and information technology to solve real problems, and it's hard to imagine more meaningful problems than the ones Adaptive is attacking," said Mr. Nolan. "The potential human benefits of Adaptive's innovations are astounding --- I'm incredibly excited and honored to join the team and be a part of that work."
Mr. Nolan will oversee Adaptive's software development and architecture, information technology, and automation.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages next generation sequencing ("NGS") to profile T-Cell and B-Cell Receptors ("TCRs" and "BCRs"). This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients.
)Adaptive's first CLIA certified clinical application, clonoSEQ(TM), is for monitoring Minimal Residual Disease ("MRD") in blood-based cancers. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.
)Adaptive incubates and validates potential clinical products in oncology, autoimmune disorders, and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQ(TM). Adaptive will be introducing an immunoSEQ Kit for research use only in the fall of 2014 to facilitate the integration of immunosequencing into research centers globally.
Using the immunoSEQ platform, the company is currently validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TIL") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.
SOURCE Adaptive Biotechnologies Corporation